Search results for Retatrutide

Trial of next-gen weight-loss drug retatrutide brings it one step closer to FDA approval

While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors

Meet Retatrutide: The Unapproved Cousin Of Zepbound That Supports Weight Loss Differently – California Trim Clinic Revea...

Zepbound quickly became one of the most talked-about weight loss medications in recent years. For many patients, it delivered something they had been searching for--real, visible p...

642 DUODENAL MUCOSAL RESURFACING PREVENTS WEIGHT REGAIN AFTER TIRZEPATIDE WITHDRAWAL: REMAIN-1 MULTICENTER, RANDOMIZED,...

The Weight Loss World’s Worst-Kept Secret? Why Retatrutide Is Suddenly Everywhere Before FDA Approval, California Trim C...

Retatrutide has not reached FDA approval, but the patient rush has already started. As clinical-trial buzz, social media chatter, plateau frustration, and gray-market curiosity col...

Retatrutide results spark questions about how rapid weight loss affects the body

New-generation GLP-1 drugs, such as retatrutide, are achieving higher rates of weight loss. How much weight is too much and too fast to lose?

Why Retatrutide Is Being Called The Next Frontier In Weight Loss Drugs

The world of weight management is evolving faster than ever, and a new drug discovery is setting a historic milestone for obesity treatment.

After early Semaglutide lead, Torrent Pharma eyes US liver drug Resmetirom for India launch

Resmetirom is the first approved therapy in the US specifically for MASH, earlier known as NASH—a progressive fatty liver disease linked to obesity, diabetes and poor metabolic hea...

A New Obesity Drug Delivered Surgery-Level Weight Loss in Clinical Trials

Learn about retatrutide, a new weight-loss drug that works differently than other GLP-1s and helped patients in a clinical trial lose up to 85 pounds.

<![CDATA[Travere Therapeutics’ Filspari Receives Full FDA Approval ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Datroway]]>

Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial

Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study...

He Tried Dieting, Training, Even Testosterone — But Nothing Touched His Belly Fat. Then Retatrutide Changed Everything –...

For many men over 40, the most frustrating part of fat loss is not a lack of effort. It is the moment when disciplined eating, consistent training, and even years of testosterone t...

A New Weight-Loss Drug Just Outperformed Popular GLP-1s. Here’s What It Means for the Future of Health

Retatrutide, Eli Lilly’s new experimental drug, helped some participants lose up to 28 percent of their body weight in clinical trials.

559 REAL WORLD GI SAFETY COMPARISON OF SEMAGLUTIDE AND TIRZEPATIDE: A PHARMACOVIGILANCE STUDY

Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile

As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in...